| 孙龙龙,孙 斌,马玉春,雷红召,董长宪.普萘洛尔与阿替洛尔治疗增殖期婴幼儿血管瘤的临床疗效及安全性对比[J].,2018,(1):108-112 |
| 普萘洛尔与阿替洛尔治疗增殖期婴幼儿血管瘤的临床疗效及安全性对比 |
| Comparison of the Efficacy and Safety of Propranolol and Atenolol in the Treatment of Infant Hemangioma |
| 投稿时间：2017-08-20 修订日期：2017-09-15 |
| DOI：10.13241/j.cnki.pmb.2018.01.024 |
| 中文关键词: 婴幼儿血管瘤 普萘洛尔 阿替洛尔 治疗 |
| 英文关键词: Infantile hemangioma Propranolol Atenolol Treatment |
| 基金项目:河南省医学科技攻关项目（201403152） |
|
| 摘要点击次数: 405 |
| 全文下载次数: 269 |
| 中文摘要: |
| 摘要 目的：对比普萘洛尔与阿替洛尔对增殖期婴幼儿血管瘤临床疗效及安全性。方法：选择2015年2月至2016年7月符合入选标准的血管瘤婴儿患者173例，分为普萘洛尔组91例和阿替洛尔组82例，分别给予普萘洛尔与阿替洛尔连续治疗24周。初始1周为每天随访，之后为每月随访一次。治疗6个月后，比较两组婴儿血管瘤的消退面积、不良反应率、反应的频率和严重程度。结果：普萘洛尔组57例(63%)患者治愈(瘤体缩小75%-100%)，阿替洛尔组46例(56.3％)患者治愈(瘤体缩小75%-100%)，两组治愈率对比差异无统计学意义(P>0.05)。普萘洛尔组有11例因不能耐受药物不良反应及患者家属原因退出治疗，阿替洛尔组有2例因不能耐受药物不良反应及患者家属原因退出治疗，阿替洛尔组重度不良反应率显著低于普萘洛尔组(P=0.025)。普萘洛尔组轻中度不良事件为85例(94%)，阿替洛尔组为62例(75%)，两组比较差异无统计学意义(P>0.05)。阿替洛尔组治疗时间较普萘洛尔缩短(314天vs 297天)(P<0.05)。结论：普萘洛尔与阿替洛尔治疗婴幼儿血管瘤的临床疗效和安全性相当，但阿替洛尔的耐受性和依从性更好，重度不良反应明显减少。 |
| 英文摘要: |
| ABSTRACT Objective: To compare the efficacy and safety of propranolol and atenolol in the treatment of infantile hemangioma during proliferative stage. Methods: From February 2015 to July 2016, 173 cases of patients with infantile hemangioma selected and di- vided into 91 patients in the propranolol group and 82 patients in the atenolol group. They were continuously given propranolol or atenolol treatment for 24 weeks. The first week was followed up for each day, followed by once a month. At 6 months after treatment, the regression area, adverse rate of response, frequency and severity of response were compared between the two groups. Results: 57 patients (63%) were cured (Tumor size decreased 75% -100%) in the propranolol group and 46 patients (56.3%) cured (Tumor size decreased 75% -100%) in the atenolol group, no statistically significance difference was found between the two groups(P>0.05). 11 cases in the pro- pranolol group were unable to tolerate adverse drug reactions and patients withdrawn from the treatment, 2 cases in the atenolol group can not tolerate adverse drug reactions and patients withdrawn from treatment, the rate of severe adverse reactions in the atenolol group was significantly lower than that in the propranolol group (P=0.025). The incidence of mild to moderate adverse events was 85 cases (94%) in the propranolol group, 62 cases (75%) in the atenolol group, there was no significant difference between the two groups (P> 0.05). The average duration of treatment of atenolol group was shorter (312 days vs 297 days)(P<0.05). Conclusion: The clinical efficacy and safety of propranolol in the treatment of infantile hemangioma were equal to atenolol, however, atenolol was more tolerant and more adherent and severe adverse events were significantly reduced. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
